PE20090618A1 - Compuestos para el tratamiento de hepatitis c - Google Patents

Compuestos para el tratamiento de hepatitis c

Info

Publication number
PE20090618A1
PE20090618A1 PE2008001327A PE2008001327A PE20090618A1 PE 20090618 A1 PE20090618 A1 PE 20090618A1 PE 2008001327 A PE2008001327 A PE 2008001327A PE 2008001327 A PE2008001327 A PE 2008001327A PE 20090618 A1 PE20090618 A1 PE 20090618A1
Authority
PE
Peru
Prior art keywords
compounds
hepatitis
benzazepin
indole
treatment
Prior art date
Application number
PE2008001327A
Other languages
English (en)
Inventor
Scott W Martin
Carl P Bergstrom
Robert G Gentles
Kap-Sun Yeung
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20090618A1 publication Critical patent/PE20090618A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS HETEROCICLOS DE FORMULA (I) DONDE R1 ES CO2R5 O CONR6R7, EN DONDE R5 Y R7 SON CADA UNO H O ALQUILO; R6 ES H, ALQUILO, ALQUIL(SO2), ENTRE OTROS; R2 ES FURANILO, PIRROLILO, TIENILO, PIRAZOLILO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS CON OXO, AMINO, ALQUILTIO, ENTRE OTROS SUSTITUYENTES; R3 ES H, HALO, ALQUILO, ALQUENILO, ENTRE OTROS; R4 ES CICLOALQUILO; X ES METILENO, UN ENLACE O NO ESTA PRESENTE. SON COMPUESTOS PREFERIDOS: ESTER 1,1-DIMETILETILICO DEL ACIDO 13-CICLOHEXIL-3-METOXI-6-[2-(METOXICARBONIL)-3-TIENIL]-7H-INDOLO[2,1-a][2]BENZAZEPIN-10-CARBOXILICO, ACIDO 6-(4-CARBOXI-1-METIL-1H-PIRAZOL-5-IL)-13-CICLOHEXIL-3-METOXI-7H-INDOLO[2,1-a][2]BENZAZEPIN-10-CARBOXILICO, 13-CICLOHEXIL-3-METOXI-6-[1-METIL-4-(4-MORFOLINILCARBONIL)-1H-PIRAZOL-5-IL]-N-(4-MORFOLINILSULFONIL)-7H-INDOLO[2,1-a][2]BENZAZEPIN-10-CARBOXAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD CONTRA EL VIRUS DE LA HEPATITIS C (VHC) SIENDO UTILES EN EL TRATAMIENTO DE INFECCIONES POR HEPATITIS C
PE2008001327A 2007-08-09 2008-08-08 Compuestos para el tratamiento de hepatitis c PE20090618A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95481407P 2007-08-09 2007-08-09
US4994408P 2008-05-02 2008-05-02
US12/180,994 US7652004B2 (en) 2007-08-09 2008-07-28 Compounds for the treatment of hepatitis C

Publications (1)

Publication Number Publication Date
PE20090618A1 true PE20090618A1 (es) 2009-05-16

Family

ID=40261456

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001327A PE20090618A1 (es) 2007-08-09 2008-08-08 Compuestos para el tratamiento de hepatitis c

Country Status (18)

Country Link
US (1) US7652004B2 (es)
EP (1) EP2183252B1 (es)
JP (1) JP5465670B2 (es)
KR (1) KR20100066492A (es)
CN (1) CN101821267B (es)
AR (1) AR067897A1 (es)
AU (1) AU2008293845B2 (es)
BR (1) BRPI0814931A2 (es)
CA (1) CA2695781A1 (es)
CL (1) CL2008002353A1 (es)
CO (1) CO6251359A2 (es)
EA (1) EA015978B1 (es)
MX (1) MX2010001416A (es)
NZ (1) NZ583149A (es)
PE (1) PE20090618A1 (es)
TW (1) TW200906418A (es)
WO (1) WO2009029384A2 (es)
ZA (1) ZA201000923B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1688420A4 (en) * 2003-11-19 2008-10-22 Japan Tobacco Inc 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
AU2007361468A1 (en) * 2007-11-20 2009-05-28 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
ATE531373T1 (de) 2008-03-27 2011-11-15 Bristol Myers Squibb Co Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP2012517468A (ja) * 2009-02-11 2012-08-02 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎治療のための化合物
CN106986862A (zh) 2010-12-22 2017-07-28 Abbvie 公司 丙型肝炎抑制剂及其用途
WO2012176717A1 (ja) * 2011-06-22 2012-12-27 セントラル硝子株式会社 ピラゾール化合物の製造方法
JP5915004B2 (ja) * 2011-06-22 2016-05-11 セントラル硝子株式会社 ピラゾール化合物の製造方法
CA2879398A1 (en) * 2012-07-18 2014-01-23 Bristol-Myers Squibb Holdings Ireland Unlimited Company Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
CA2585084A1 (en) 2004-10-26 2006-05-04 Immacolata Conte Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ES2343914T3 (es) 2006-05-25 2010-08-12 Bristol-Myers Squibb Company Inhibidores de ns5b de hcv de indolobenzazepina condensada con ciclopropilo.
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Also Published As

Publication number Publication date
CO6251359A2 (es) 2011-02-21
EP2183252B1 (en) 2015-01-14
JP2010535787A (ja) 2010-11-25
JP5465670B2 (ja) 2014-04-09
CN101821267A (zh) 2010-09-01
EA015978B1 (ru) 2012-01-30
CL2008002353A1 (es) 2008-10-24
ZA201000923B (en) 2011-04-28
BRPI0814931A2 (pt) 2015-02-03
US7652004B2 (en) 2010-01-26
MX2010001416A (es) 2010-03-01
EA201000277A1 (ru) 2010-06-30
CN101821267B (zh) 2013-07-10
AR067897A1 (es) 2009-10-28
AU2008293845A1 (en) 2009-03-05
EP2183252A2 (en) 2010-05-12
US20090074715A1 (en) 2009-03-19
TW200906418A (en) 2009-02-16
WO2009029384A2 (en) 2009-03-05
KR20100066492A (ko) 2010-06-17
NZ583149A (en) 2011-07-29
WO2009029384A3 (en) 2009-05-28
CA2695781A1 (en) 2009-03-05
AU2008293845B2 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
BRPI0414176A (pt) inibidores de serina proteases, em particular hcv ns3-ns4a protease
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
PE20080418A1 (es) Compuestos y composiciones como moduladores de la via de hedgehog
BRPI0412761A (pt) inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc
PE20181804A1 (es) Derivados de aminotiazol utiles como agentes antiviricos
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
PE20121522A1 (es) Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
PE20130281A1 (es) Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
CL2011002016A1 (es) Compuestos derivados de benzimidazol con actividad inhibidora de la funcion de la proteina ns5a codificada por el virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; utiles en el tratamiento de una infeccion por el virus de la hepatitis c (vhc).
PE20090611A1 (es) Procedimiento para sintetizar compuestos utiles para tratar hepatitis c
AR074001A1 (es) Compuestos de isoindolina y composiciones farmaceuticas y uso para tratamiento de cancer
NZ592705A (en) 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
PE20040589A1 (es) Tiazolidinonas y su preparacion como medicamentos
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
EA201100482A1 (ru) Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv
PE20080070A1 (es) Derivados de indolobenzazepina fusionados a ciclopropilo como inhibidores de la polimerasa ns5b del virus de la hepatitis c
UY29457A1 (es) Compuestos novedosos de derivados de aminosulfonilo
NI201100050A (es) Derivados amida de heteroarilos su uso como activadores de glucoquinasa.
MX2009004467A (es) Compuestos benzoilo amino heterociclilo como activadores de la glucoquinasa (glk).
PE20080072A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed